Austin Private Wealth LLC Has $508,000 Stake in Pfizer Inc. (NYSE:PFE)

Austin Private Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 28.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,144 shares of the biopharmaceutical company’s stock after buying an additional 4,285 shares during the period. Austin Private Wealth LLC’s holdings in Pfizer were worth $508,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GFS Advisors LLC acquired a new stake in Pfizer during the 4th quarter valued at approximately $12,841,000. Turtle Creek Wealth Advisors LLC increased its position in shares of Pfizer by 14.6% during the fourth quarter. Turtle Creek Wealth Advisors LLC now owns 10,394 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 1,326 shares during the period. TCI Wealth Advisors Inc. raised its stake in Pfizer by 29.6% during the fourth quarter. TCI Wealth Advisors Inc. now owns 19,706 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 4,506 shares during the last quarter. Coastwise Capital Group LLC boosted its position in Pfizer by 7.7% during the fourth quarter. Coastwise Capital Group LLC now owns 72,735 shares of the biopharmaceutical company’s stock valued at $1,930,000 after acquiring an additional 5,172 shares during the last quarter. Finally, CMG Global Holdings LLC grew its holdings in Pfizer by 19.1% during the 4th quarter. CMG Global Holdings LLC now owns 18,277 shares of the biopharmaceutical company’s stock worth $475,000 after acquiring an additional 2,927 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.51 on Friday. The company has a fifty day moving average price of $26.25 and a 200-day moving average price of $27.89. The firm has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the business earned ($0.17) EPS. The company’s revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is 232.44%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Finally, Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.